CVM CEL SCI CORP

$1.03 -4.17%

Healthcare · Biological Products, (No Diagnostic Substances)

CEL SCI CORP (CVM) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $9 million. Shares last traded at $1.03, 92.2% below their 52-week high. Over the past year the stock is down 55.5%. Net profit margin is -9624.2%, below the peer median of 6.3%. Revenue grew 65.5% year over year.

Market Cap

$9M

Shares Out

8.5M

EPS (TTM)

$-13.84

P/E Ratio

—

P/S Ratio

33.29

P/B Ratio

1.28

Dividend / Share

—

Dividend Yield

—

52-Week High

$13.27

52-Week Low

$0.90

Volume

20,644

Avg Vol (3m)

11,103.73

Performance

-5.91%

-33.87%

-72.33%

-82.95%

YTD

-79.79%

-55.48%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

29.67

SMA (50)

$2.18

SMA (200)

$5.39

Price vs SMA50

-52.46%

Price vs SMA200

-80.78%

ATR (14)

$0.16

Financials

Revenue

$0M

Net Income

$-25M

Gross Margin

—

Operating Margin

-9396.5%

Net Margin

-9624.2%

Return on Equity

-369.6%

Return on Assets

-143.5%

Current Ratio

0.60

Debt / Equity

1.58

Revenue Growth (YoY)

+65.5%

Latest reported annual period ending 2014-09-30 · SEC EDGAR/XBRL.

Recent earnings

Period	EPS (diluted)	Reported
Q2 2026	$-1.35	2026-05-15
Q1 2026	$-0.68	2026-02-17
FY 2025	$-6.27	2025-12-29
Q3 2025	$-6.34	2025-08-14
Q2 2026	$-5.47	2026-05-15
Q1 2026	$-3.25	2026-02-17

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

CVM vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers

33.29 / 5.21 med

+539% premium

Net margin vs peers

-9624.2% / 6.3% med

below median

1–14 of 14


AMGN	Amgen	$182.1B	23.62	4.96	21.0%	-1.27%
GILD	Gilead Sciences	$153.5B	18.04	5.21	28.9%	-1.46%
RVMD	Revolution Medicines, Inc.	$34.6B	-30.62	—	—	+3.14%
BIIB	Biogen	$29.0B	22.44	2.93	13.1%	-1.15%
MRNA	Moderna	$25.4B	-8.99	—	—	+3.22%
NBIX	Neurocrine Biosciences Inc	$15.9B	33.24	5.56	16.7%	-0.48%
EXEL	Exelixis, Inc.	$13.1B	16.68	5.62	33.7%	-1.04%
KRYS	Krystal Biotech, Inc.	$10.2B	50.02	26.33	52.6%	+1.68%
TECH	Bio-Techne	$9.1B	123.61	7.44	6.0%	+5.36%
HALO	Halozyme Therapeutics, Inc.	$8.1B	25.67	5.82	22.7%	-0.03%
IBRX	Immunitybio, Inc.	$7.7B	-21.87	—	—	+5.01%
RGEN	Repligen Corp	$7.4B	152.27	10.08	6.6%	-1.20%
KYMR	Kymera Therapeutics, Inc.	$7.4B	23.88	—	—	+0.44%
PCVX	Vaxcyte, Inc.	$7.4B	-9688.00	—	—	+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.